Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
1090
resultados
Última actualización
02/08/2026 [06:57:00]
Resumen de: US20260216375A1
0000 Certain aspects of the invention are directed to methods of making a concentrated nucleic acid composition comprising: (a) combining (i) a DNA plasmid comprising a nucleic acid encoding a human IL-12 polypeptide, (ii) a cationic lipopolymer comprising polyethylene glycol (PEG)-polyethylenimine (PEI)-cholesterol (PPC), and (iii) a filler excipient in an aqueous medium, wherein the nucleic acid complexes with the cationic lipopolymer, thereby forming a nucleic acid mixture having a concentration of at least 0.15 mg/mL; and (b) concentrating the nucleic acid mixture of (a) by tangential flow filtration to form a concentrated nucleic acid composition having a concentration of at least 0.75 mg/mL, wherein the concentrated nucleic acid composition is suitable for pharmaceutical use, storage at −20° C. or less, 4° C. or less, and/or lyophilization. The invention further relates to pharmaceutical compositions prepared using the disclosed methods and methods of using the same.
Resumen de: US20260216236A1
A composition for treating hyperprocalcitonemia is described. The composition comprises a lipophilic or hydrophobic component, an amphiphilic emulsifier, a polar liquid carrier, and with or without one or more electrolytes, where the amphiphilic emulsifier forms micelles having a lipophilic or hydrophobic core comprising the lipophilic or hydrophobic component in the polar liquid carrier, and/or liposomes organized as a lipid bilayer and/or other particle configurations.
Resumen de: US20260216335A1
0000 Nanoparticles encapsulating core particles with attached photothermal agents, and therapeutic agents. The methods of imaging a tumor tissue and/or treating a subject suffering from tumor with the nanoparticles provided herein.
Resumen de: US20260216095A1
Provided herein, inter alia, are hydrogel compositions, and use thereof for treatment of a tissue in a subject and monitoring the treatment.
Resumen de: US20260216319A1
0000 The present disclosure provides for methods of inducing an immune response against varicella zoster virus (VZV) in a human subject. The methods provided herein comprise administering immunogenic compositions (e.g., vaccines) comprising RNA molecules formulated in a lipid nanoparticle to a human subject. The present disclosure further relates to the use of immunogenic compositions for preventing or treating of Herpes zoster in a human subject.
Resumen de: US20260216071A1
0000 Nanoparticulate compositions are disclosed. The nanoparticulate compositions typically include at least one, preferably two or more, active agent(s), one of which is an immunomodulatory compound, loaded into, attached to the surface of, and/or enclosed within a delivery vehicle. The delivery vehicles can be nanolipogels including a polymeric core and a lipid shell or a biodegradable polymeric nanoparticle such as a PLGA nanoparticle. Typically, at least one of the active agents is an immunomodulator that increases an immune stimulatory response or decreases an immune suppressive response. In some embodiments, the particle includes both an immunomodulator that increases an immune stimulatory response and an immunomodulator that decreases an immune suppressive response. The particles can be decorated with a targeting moiety that improves delivery to a target cell. Methods of using the compositions to enhance an immune response and treat diseases such as cancer are also disclosed.
Resumen de: US20260216085A1
Biocompatible and biodegradable nanoparticles based on amorphous calcium phosphate containing ascorbic acid and anti-tumor agents. The use of these nanoparticles as highly stable nanocarriers of these drugs improves their effectiveness in terms of bioavailability, cytotoxicity, induction of apoptosis, inhibition of cell migration, tumor growth and survival. These nanoparticles may be obtained by mixing a solution of CaCl2 and Na3C6H5O7 and a solution of K2HPO4 and Na2CO3, adsorbing one or more PARP inhibitors, and adsorbing ascorbic acid.
Resumen de: US20260216072A1
0000 A composition comprising: (a) an active ingredient; and (b) a lipid mixture comprising: (i) a cationically ionisable lipid capable of forming a lipid nanoparticle; (ii) a steroid; and (iii) a negatively charged amphiphile having a hydrophilic portion and a lipophilic portion; wherein the composition is a lipid nanoparticle composition and is substantially free of a polyethylene glycol-conjugated lipid, wherein the polyethylene glycol (PEG) moiety of the PEG-conjugated lipid has at least 5 consecutive ethylene glycol repeating units, is provided.
Resumen de: US20260216313A1
0000 The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of ribonucleic acid immunogenic compositions and/or vaccines comprising polynucleotide molecules preferably encoding one or more influenza antigens, such as hemagglutinin antigens, wherein the composition is frozen or lyophilized.
Resumen de: US20260216015A1
0000 The present invention relates to pH-sensitive nanoparticles including a cationic substance which may stably encapsulate an active substance at a high content and having an excellently improved skin retention and delivery of the active ingredient when applied to skin, and a composition including the same.
Resumen de: US20260216368A1
0000 The present invention provides, in part, bis-ester and amide cationic lipid compounds of Formula (I): or a pharmaceutically acceptable salt thereof, bis-ester and amide cationic lipid compounds of Formula (II): or a pharmaceutically acceptable salt thereof, bis-ester and amide cationic lipid compounds of Formula (III): or a pharmaceutically acceptable salt thereof, and bis-ester and amide cationic lipid compounds of Formula (IV): or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
0000
Resumen de: US20260218151A1
0000 The present disclosure provides a method for delivery of nucleic acid to a T cell to produce a modified T cell, the method comprising contacting a lipid nanoparticle encapsulating the nucleic acid with the T cell ex vivo or in vivo, thereby causing cellular uptake of the nucleic acid, the lipid nanoparticle having between 30 mol % and 70 mol % of a neutral or zwitterionic amphipathic lipid having a net-neutral charge at physiological pH, an ionizable cationic lipid, and a sterol, wherein the lipid nanoparticle is substantially uncharged at physiological pH and has an apparent pKa of between 6.0 and 7.5, wherein the nucleic acid modifies the T cell to provide a T cell having a therapeutic, prophylactic or ameliorative effect in vivo. Further provided are compositions for use thereof and T cell preparations.
Resumen de: US20260216093A1
Described herein are compositions and methods for enhanced drug loading into lipid-based carriers. The compositions and methods may comprise a drug-bound chiral graphene quantum dot comprising a graphene quantum dot functionalized with a non-aromatic chiral ligand having a single chiral center, wherein a chirality of the chiral graphene quantum dot matches a chirality of a lipid content of the lipid-based carrier. The drug-bound chiral graphene quantum dot permeates into the lipid-based carrier via matching of the chirality of the chiral graphene quantum dot to the chirality of the lipid content of the lipid-based carrier to load the drug into the lipid-based carrier. The compositions and methods achieve a drug loading efficiency of greater than 60% into lipid-based carriers.
Resumen de: US20260216073A1
0000 Method of manufacturing an aqueous suspension of hybrid lipid particles comprising the steps of mixing one or more lipids in a solvent or solvent mixture and a suspension of particles of inorganic material in a solvent or solvent mixture, into an aqueous medium; then passing the mixture resulting from Step A through the pores of an extrusion membrane, wherein the hybrid lipid particles have a mean diameter at least two times larger than the mean diameter of the particles of inorganic material. Related product, methods of treatment and medical application.
Resumen de: US20260216328A1
The present disclosure provides switchable bispecific T cell engagers (switch-BiTEs or SiTEs). In certain embodiments, the switch-BiTEs comprise a disruptable linker. The present disclosure further relates to methods of treating cancer and methods of generating responses in vivo comprising use of the switch-BiTEs of the present disclosure.
Resumen de: US20260216334A1
0000 The present disclosure provides compositions comprising biogels and hydrogels comprising lipid nanoparticles (LNPs) comprising nucleic acids encoding target antigens along with modified immune cells or precursors thereof (e.g., T cells) comprising chimeric antigen receptors (CARs). Methods of treating disease (e.g., cancer) by administering said compositions to a subject in need thereof, are also provided.
Resumen de: US20260216088A1
0000 One or more ionizable lipid(s) and lipid nanoparticles comprising same and further encapsulating a polynucleic acid are provided. Pharmaceutical compositions comprising a therapeutically effective amount of the lipid nanoparticles encapsulating a therapeutically active polynucleic acid are also provided. Pharmaceutical compositions are used in delivering of the polynucleic acid to a lung tissue of a subject are also provided.
Resumen de: US20260217645A1
0000 An amino lipid compound, and a preparation method therefor and the use thereof. The present invention further relates to a lipid nanoparticle and a pharmaceutical composition containing the amino lipid compound, and the use thereof.
Resumen de: AU2025213008A1
An ionizable lipid of formula (I) or a pharmaceutically acceptable salt thereof, or a stereoisomer of any one of them; a lipid nanoparticle comprising the ionizable lipid, particularly, as an encapsulation agent, optionally comprising a pharmaceutically active agent; and a pharmaceutical composition comprising the lipid nanoparticle. A lipid nanoparticle or a pharmaceutical composition comprising thereof for use in medicine, and the use of the lipid nanoparticles as an encapsulating agent.
Resumen de: AU2024403484A1
The present invention relates to the field of lipid nanoparticles (LNP); more specifically comprising an ionizable lipid, a phospholipid, a sterol, a PEG lipid and one or more nucleic acids. The LNP's of the present invention are characterized in having an ionizable lipid content of above 55 mol% and a ratio of cholesterol to phospholipid of 1 : 1 or less, such as about 1 : 2 or less. The present invention provides use of the LNP's for extrahepatic deliveryof nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in the treatment of cancer, autoimmune diseases, genetic disorders, hematological disorders, aging, fibrosis, neurological disorders, cardiovascular diseases or infectious diseases.
Resumen de: AU2025212594A1
The present disclosure provides methods of preparing lipid nanoparticle (LNP) formulations. The present disclosure also provides therapeutic and diagnostic uses related to the prepared LNP formulations.
Resumen de: AU2024397442A1
An immunomodulatory combination that includes a first lipid conjugate, a second lipid conjugate, and one or more nucleic acids. The first lipid conjugate includes a corticosteroid covalently linked to a first lipophilic moiety by a first cleavable linkage or through a first cleavable linker. The second lipid conjugate includes an mTOR/mTORC inhibitor covalently linked to a second lipophilic moiety by a second cleavable linkage or through a second cleavable linker. The one or more nucleic acids encode one or more epitopes targeted by autoreactive T cells, wherein the one or more epitopes comprise one or more class II epitopes. The first lipid conjugate, the second lipid conjugate, and the one or more nucleic acids are co-formulated together in a delivery vehicle, or are formulated in two or three separate delivery vehicles. The immunomodulatory combination may be used for treating autoimmune diseases or conditions involving autoreactive T cells, which includes both CD4+ T cells and CD8+ T cells.
Resumen de: US20260217744A1
The application is related to compounds of Formula I, their uses and lipid nanoparticle formulations
Resumen de: US20260217920A1
0000 A composite nanoparticle that includes a biodegradable amphiphilic material and a hydrophobic compound having a stable isotope label. The biodegradable amphiphilic material may be a polymeric, non-polymeric, or hybrid polymer/lipid self-assembling system. The composite nanoparticle may be a poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-b-PCL) copolymer, a poly(ethylene glycol)-block-poly(L-lactide) (PEG-b-PLA) copolymer, or poly(ethylene glycol)-block-poly(lactide-co-glycolide) (PEG-b-PLGA) copolymer; and the poly(ethylene glycol) block of any of the polymeric biodegradable amphiphilic copolymers may be poly(ethylene glycol) or methoxy poly(ethylene glycol). The hydrophobic compound of the composite nanoparticle may be a fatty acid, a fatty acid derivative, and a lipid analog having a stable isotope label. Compositions and methods of using and making the composite nanoparticle.
Nº publicación: US20260216531A1 30/07/2026
Solicitante:
BECKMAN CHRISTOPHER V [US]
Beckman Christopher V
Resumen de: US20260216531A1
0000 New techniques for remote application of medicine and small-scaled medical devices within a living body using remote guidance and activation systems are provided. In some embodiments, a small-scaled medical device is remotely guided and driven into the treatment target within a living body (e.g., a human body). The design of such a device (e.g., an injectable machine) may include a sub-device, e.g., a medical payload-carrying reservoir and/or abrasive tool, which may be activated magnetically and/or by radiation. In other aspects, the device is provided with multiple dipoles, each oriented differently in three-dimensional space, allowing a guidance control system, remote from the medicine or device, to drive the movement and three-dimensional orientation of the medical agent or particle according to a three-dimensional path. In other aspects, a radiation shield is introduced within the living body, and the radiation targets both a treatment target and the radiation shield.
BOPI
Sede Electrónica
